Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.
CARD11
atopic dermatitis
atopy
dominant negative
immune dysregulation
primary immunodeficiency
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
23
04
2018
revised:
02
08
2018
accepted:
13
08
2018
pubmed:
1
9
2018
medline:
24
4
2020
entrez:
1
9
2018
Statut:
ppublish
Résumé
Caspase activation and recruitment domain 11 (CARD11) encodes a scaffold protein in lymphocytes that links antigen receptor engagement with downstream signaling to nuclear factor κB, c-Jun N-terminal kinase, and mechanistic target of rapamycin complex 1. Germline CARD11 mutations cause several distinct primary immune disorders in human subjects, including severe combined immune deficiency (biallelic null mutations), B-cell expansion with nuclear factor κB and T-cell anergy (heterozygous, gain-of-function mutations), and severe atopic disease (loss-of-function, heterozygous, dominant interfering mutations), which has focused attention on CARD11 mutations discovered by using whole-exome sequencing. We sought to determine the molecular actions of an extended allelic series of CARD11 and to characterize the expanding range of clinical phenotypes associated with heterozygous CARD11 loss-of-function alleles. Cell transfections and primary T-cell assays were used to evaluate signaling and function of CARD11 variants. Here we report on an expanded cohort of patients harboring novel heterozygous CARD11 mutations that extend beyond atopy to include other immunologic phenotypes not previously associated with CARD11 mutations. In addition to (and sometimes excluding) severe atopy, heterozygous missense and indel mutations in CARD11 presented with immunologic phenotypes similar to those observed in signal transducer and activator of transcription 3 loss of function, dedicator of cytokinesis 8 deficiency, common variable immunodeficiency, neutropenia, and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome. Pathogenic variants exhibited dominant negative activity and were largely confined to the CARD or coiled-coil domains of the CARD11 protein. These results illuminate a broader phenotypic spectrum associated with CARD11 mutations in human subjects and underscore the need for functional studies to demonstrate that rare gene variants encountered in expected and unexpected phenotypes must nonetheless be validated for pathogenic activity.
Sections du résumé
BACKGROUND
Caspase activation and recruitment domain 11 (CARD11) encodes a scaffold protein in lymphocytes that links antigen receptor engagement with downstream signaling to nuclear factor κB, c-Jun N-terminal kinase, and mechanistic target of rapamycin complex 1. Germline CARD11 mutations cause several distinct primary immune disorders in human subjects, including severe combined immune deficiency (biallelic null mutations), B-cell expansion with nuclear factor κB and T-cell anergy (heterozygous, gain-of-function mutations), and severe atopic disease (loss-of-function, heterozygous, dominant interfering mutations), which has focused attention on CARD11 mutations discovered by using whole-exome sequencing.
OBJECTIVES
We sought to determine the molecular actions of an extended allelic series of CARD11 and to characterize the expanding range of clinical phenotypes associated with heterozygous CARD11 loss-of-function alleles.
METHODS
Cell transfections and primary T-cell assays were used to evaluate signaling and function of CARD11 variants.
RESULTS
Here we report on an expanded cohort of patients harboring novel heterozygous CARD11 mutations that extend beyond atopy to include other immunologic phenotypes not previously associated with CARD11 mutations. In addition to (and sometimes excluding) severe atopy, heterozygous missense and indel mutations in CARD11 presented with immunologic phenotypes similar to those observed in signal transducer and activator of transcription 3 loss of function, dedicator of cytokinesis 8 deficiency, common variable immunodeficiency, neutropenia, and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome. Pathogenic variants exhibited dominant negative activity and were largely confined to the CARD or coiled-coil domains of the CARD11 protein.
CONCLUSION
These results illuminate a broader phenotypic spectrum associated with CARD11 mutations in human subjects and underscore the need for functional studies to demonstrate that rare gene variants encountered in expected and unexpected phenotypes must nonetheless be validated for pathogenic activity.
Identifiants
pubmed: 30170123
pii: S0091-6749(18)31201-6
doi: 10.1016/j.jaci.2018.08.013
pmc: PMC6395549
mid: NIHMS1505504
pii:
doi:
Substances chimiques
CARD Signaling Adaptor Proteins
0
CARD11 protein, human
EC 4.6.1.2
Guanylate Cyclase
EC 4.6.1.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1482-1495Subventions
Organisme : NIAID NIH HHS
ID : R21 AI109187
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG006542
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AI001183-04
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Wellcome Trust
ID : 207556/Z/17/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Elsevier Inc.
Références
J Immunol. 1999 Nov 1;163(9):5116-24
pubmed: 10528218
Immunity. 2003 Jun;18(6):751-62
pubmed: 12818157
Am J Hum Genet. 2006 Jun;78(6):922-35
pubmed: 16685644
J Immunol. 2007 Apr 1;178(7):4373-84
pubmed: 17371994
J Biol Chem. 2007 Jun 8;282(23):17141-7
pubmed: 17428801
Nat Immunol. 2008 Mar;9(3):272-81
pubmed: 18264101
Science. 2008 Mar 21;319(5870):1676-9
pubmed: 18323416
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Cold Spring Harb Perspect Biol. 2010 Sep;2(9):a003004
pubmed: 20685844
J Exp Med. 2012 Nov 19;209(12):2247-61
pubmed: 23129749
Mol Cell Biol. 2013 Jan;33(2):429-43
pubmed: 23149938
Bioinformatics. 2013 Jan 15;29(2):197-205
pubmed: 23162081
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
J Allergy Clin Immunol. 2013 Feb;131(2):477-85.e1
pubmed: 23374270
J Allergy Clin Immunol. 2013 May;131(5):1376-83.e3
pubmed: 23561803
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Sci Signal. 2014 Jun 10;7(329):ra55
pubmed: 24917592
Nat Rev Immunol. 2014 Jul;14(7):435-46
pubmed: 24962260
J Allergy Clin Immunol. 2014 Aug;134(2):276-84
pubmed: 25087226
J Clin Immunol. 2015 Jan;35(1):32-46
pubmed: 25352053
Nat Commun. 2015 Jan 20;6:5555
pubmed: 25602919
Mol Immunol. 2015 Dec;68(2 Pt C):546-57
pubmed: 26260210
Blood. 2015 Oct 1;126(14):1658-69
pubmed: 26289640
J Biol Chem. 2016 Apr 15;291(16):8338-48
pubmed: 26884334
J Biol Chem. 2016 Apr 15;291(16):8324-36
pubmed: 26884335
Nat Rev Immunol. 2016 Apr;16(4):234-46
pubmed: 26996199
Curr Opin Hematol. 2016 Jul;23(4):402-9
pubmed: 27135977
Biol Chem. 2016 Dec 1;397(12):1315-1333
pubmed: 27420898
J Allergy Clin Immunol. 2016 Oct;138(4):957-969
pubmed: 27720020
Nat Genet. 2017 Aug;49(8):1192-1201
pubmed: 28628108
J Allergy Clin Immunol. 2018 Apr;141(4):1427-1438
pubmed: 28782633
J Allergy Clin Immunol. 2018 May;141(5):1818-1830.e2
pubmed: 28826773
Front Immunol. 2018 Feb 08;9:198
pubmed: 29472930
J Exp Med. 2018 Apr 2;215(4):1009-1022
pubmed: 29549114